Study on Levothyroxine for Subclinical Hypothyroidism in Older Adults

Research Background

In a 2017 study, researchers examined the risks and benefits of levothyroxine in treating subclinical hypothyroidism among older adults. The results indicated that levothyroxine does not enhance symptoms associated with hypothyroidism. This condition, characterized by insufficient production of the thyroid hormone thyroxine and excessive secretion of thyroid-stimulating hormone (TSH) from the pituitary gland, can severely impact various bodily functions, including digestion, metabolism, muscle strength, and memory.

Understanding Subclinical Hypothyroidism

Subclinical hypothyroidism occurs when thyroxine levels remain within normal limits, yet patients may not exhibit hallmark symptoms such as weight gain, fatigue, hair loss, or temperature sensitivity. This condition is thought to contribute to various health issues in older adults. However, current evidence regarding the safety and effectiveness of thyroxine replacement therapy for this demographic is limited.

Study Overview

A recent trial published in the New England Journal of Medicine investigated the safety and efficacy of levothyroxine (a synthetic form of thyroxine) for treating subclinical hypothyroidism. The study involved otherwise healthy participants aged 65 and older who had been diagnosed with subclinical hypothyroidism for a duration of 3 months to 3 years. Participants had TSH levels ranging from 4.60 to 19.99 mIU/L and free thyroxine levels between 0.7 and 1.9 ng/dL. Individuals receiving treatment for hypothyroidism were excluded from the study.

Study Methodology

Patients were categorized based on country, age, and sex and were randomly assigned to receive either 50 μg of levothyroxine (or 25 μg for those with coronary heart disease or weighing under 50 kg) or a placebo for a duration of 12 months. Doses were adjusted as needed to achieve TSH levels between 0.40 and 4.59 mIU/L. The assessment of efficacy focused on thyroid symptoms and quality of life, measured through various scales, including ThyPRO and EQ-5D. Safety was evaluated based on adverse events such as irregular heart rhythms and fractures.

Study Results

A total of 737 patients participated in the study, with 368 receiving levothyroxine and 369 receiving a placebo. The average age of participants was 74.4 years, and 53.7% were women. On the ThyPRO scale, 27.0% scored zero on the symptomatic component, while 8.7% scored zero on the fatigue component. Follow-up for at least 12 months was achieved for 90.2% of the levothyroxine group and 91.3% of the placebo group.

Initial TSH levels averaged 6.4 mIU/L. After 6-8 weeks of treatment, TSH levels dropped by 2.29 mIU/L in the levothyroxine group compared to the placebo group, and by 12 months, this difference was reduced to 1.92 mIU/L. Free thyroxine levels were also higher in the levothyroxine group.

However, there were no significant differences in symptomatic scores or quality of life metrics between the two groups after 12 months. In an extended analysis, levothyroxine patients reported slightly lower tiredness scores than those on placebo.

Conclusion and Recommendations

Overall, the study concluded that levothyroxine does not significantly alleviate symptoms of subclinical hypothyroidism in older adults compared to a placebo. Furthermore, the safety profile showed no significant advantage in reducing adverse events. The authors highlighted the need for future research with a more diverse participant pool, especially considering various underlying causes of hypothyroidism, to clarify the potential benefits or risks of levothyroxine treatment.

Source

Haynes, R. (2017). Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism. N Engl J Med, 376: 2534-2544. DOI: 10.1056/NEJMoa1603825.